Profile of Psoriasis Vulgaris Patients Treated with Methotrexate at Dr. Soetomo Hospital, Surabaya, 2017–2018
Downloads
Background: Psoriasis Vulgaris is a chronic inflammatory skin disease that affects patients' quality of life. Methotrexate is the first-line and most effective systemic therapy in psoriasis vulgaris management. Purpose: The aim of this study was to evaluate clinical improvement after methotrexate therapy and any adverse effects of methotrexate therapy in psoriasis vulgaris management. Methods: The data for this descriptive, retrospective study were retrieved from the medical records of 22 psoriasis vulgaris patients who were treated with methotrexate therapy between January 2017 and June 2018 in the Child Kemuning Ward (IRNA), Dr. Soetomo General Hospital in Surabaya, East Java. Results: Data for a total of 22 subjects were collected for this study. The majority of the subjects were in the age group 25–59, and the average age was 40.50±17.20. Good clinical improvement (decrease in the body surface area of the lesion) was found in all patients. The adverse effects of methotrexate were evaluated based on the elevation of liver and renal function test levels. An elevation of aspartate aminotransferase levels was found in 11 patients, and an elevation in alanine aminotransferase levels was found in 13 patients. Elevated blood urea nitrogen levels were found in eight patients, and elevated serum creatinine levels were found in four patients. Conclusion: Methotrexate is an effective treatment for severe psoriasis vulgaris management when administered with careful selection and regular monitoring of patients. Application of methotrexate therapy in accordance with the guidelines remains suitable for psoriasis vulgaris management with vigilance regarding methotrexate's adverse effects.
Ahmadzadeh, A., Zamani, N., Hassanian-Moghaddam, H., Hadeiy, S. K., & Parhizgar, P. (2019). Acute versus chronic methotrexate poisoning; a cross-sectional study. BMC Pharmacology and Toxicology, 20(1), 1–7. https://doi.org/10.1186/s40360-019-0316-8
Arakawa, Y., Arakawa, A., Vural, S., Mahajan, R., & Prinz, J. C. (2019). Renal clearance and intracellular half-life essentially determine methotrexate toxicity: a case series. JAAD Case Reports, 5(1), 98–100. https://doi.org/10.1016/j.jdcr.2018.10.022
Cheng, H., & Rademaker, M. (2018). Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis: Targets and Therapy, 8, 21–29. https://doi.org/10.2147/ptt.s141629
Conway, R., & Carey, J. J. (2017). Risk of liver disease in methotrexate treated patients. World Journal of Hepatology, 9(26), 1092–1100. https://doi.org/10.4254/wjh.v9.i26.1092
Czarnecka-Operacz, M., & Sadowska-Przytocka, A. (2014). The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatologii i Alergologii, 31(6), 392–400. https://doi.org/10.5114/pdia.2014.47121
Elango, T., Thirupathi, A., Subramanian, S., Ethiraj, P., Dayalan, H., & Gnanaraj, P. (2017). Methotrexate treatment provokes apoptosis of proliferating keratinocyte in psoriasis patients. Clinical and Experimental Medicine, 17(3), 371–381. https://doi.org/10.1007/s10238-016-0431-4
Gisondi, P., Pezzolo, E., & Girolomoni, G. (2019). Glomerular filtration rate in patients with moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology, 33(6), e244–e246. https://doi.org/10.1111/jdv.15506
Gudjonsson, J. E., & Elder, J. T. (2019). Psoriasiform disorders. In S. Kang, M. Amagai, A. L. Bruckner, A. H. Enk, D. J. Margolis, A. J. McMichael, & J. S. Orringer (Eds.), Fitzpatrick's Dermatology (9th edition, pp. 457–497). USA: Cenveo® Publisher Services.
Kivity, S., Zafrir, Y., Loebstein, R., Pauzner, R., Mouallem, M., & Mayan, H. (2014). Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients. Autoimmunity Reviews, 13(11), 1109–1113. https://doi.org/https://doi.org/10.1016/j.autrev.2014.08.027
Labadie, J. G., & Jain, M. (2019). Noninvasive tests to monitor methotrexate-induced liver injury. Clinical Liver Disease, 13(3), 67–71. https://doi.org/10.1002/cld.765
Madke, B., & Singh, A. L. (2015). Acute methotrexate toxicity. Indian Journal of Drugs Dermatology, 1(1), 46–49.
Nast, A., Gisondi, P., Ormerod, A. D., Saiag, P., Smith, C., Spuls, P. I., ... Yawalkar, N. (2015). European S3-guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version – EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology, 29(12), 2277–2294. https://doi.org/10.1111/jdv.13354
Nast, A., Spuls, P. I., van der Kraaij, G., Gisondi, P., Paul, C., Ormerod, A. D., ... Dressler, C. (2017). European S3-guideline on the systemic treatment of psoriasis vulgaris – update apremilast and secukinumab – EDF in cooperation with EADV and IPC. Journal of the European Academy of Dermatology and Venereology, 31(12), 1951–1963. https://doi.org/10.1111/jdv.14454
Shaikh, N., Sardar, M., Raj, R., & Jariwala, P. (2018). A rapidly fatal case of low-dose methotrexate toxicity. Case Reports in Medicine, 2018, 1–4. https://doi.org/10.1155/2018/9056086
Vollenbroek, F. T. M. B. op, Doggen, C. J. M., Janssens, R. W. A., & Moens, H. J. B. (2018). Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines. PLoS ONE, 13(3), 1–11. https://doi.org/10.1371/journal.pone.0194401
Warren, R. B., Weatherhead, S. C., Smith, C. H., Exton, L. S., Mohd Mustapa, M. F., Kirby, B., & Yesudian, P. D. (2016). British association of dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 175(1), 23–44. https://doi.org/10.1111/bjd.14816
Weidmann, A., Foulkes, A. C., Kirkham, N., & Reynolds, N. J. (2014). Methotrexate toxicity during treatment of chronic plaque psoriasis: a case report and review of the literature. Dermatology and Therapy, 4(2), 145–156. https://doi.org/10.1007/s13555-014-0056-z
West, J., Ogston, S., Berg, J., Palmer, C., Fleming, C., Kumar, V., & Foerster, J. (2017). HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. Clinical and Experimental Dermatology, 42(6), 651–655. https://doi.org/10.1111/ced.13100
West, J., Ogston, S., & Foerster, J. (2016). Safety and efficacy of methotrexate in psoriasis: a meta-analysis of published trials. PLoS ONE, 11(5), 1–14. https://doi.org/10.1371/journal.pone.0153740
Yélamos, O., & Puig, L. (2015). Systemic methotrexate for the treatment of psoriasis. Expert Review of Clinical Immunology, 11(5), 553–563. https://doi.org/10.1586/1744666x.2015.1026894
- Every manuscript submitted to must observe the policy and terms set by the Jurnal Berkala Epidemiologi
- Publication rights to manuscript content published by the Jurnal Berkala Epidemiologi is owned by the journal with the consent and approval of the author(s) concerned. (download copyright agreement)
- Complete texts of electronically published manuscripts can be accessed free of charge if used for educational and research purposes according to copyright regulations.
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
